The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2019 | Molecular therapy stratification for high-risk MM: MUK Nine b OPTIMUM
Martin Kaiser, MD, Royal Marsden NHS Foundation Trust, London, UK, discusses the MUK Nine b: OPTIMUM Treatment Protocol (NCT03188172), a phase II trial for transplant eligible newly diagnosed multiple myeloma (NDMM) patients. This study consisted of two inter-related protocols: a molecular screening protocol and an interventional trial for high-risk NDMM identified in the molecular screening. Dr Kaiser highlights the innovative therapy used in this trial. This interview took place at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.
